174 related articles for article (PubMed ID: 35871521)
1. The Effect of Nusinersen Therapy on Laboratory Parameters of Patients with Spinal Muscular Atrophy.
Sarıkaya Uzan G; Paketçi C; Günay Ç; Edem P; Özsoy Ö; Hız Kurul S; Yiş U
Neuropediatrics; 2022 Oct; 53(5):321-329. PubMed ID: 35871521
[TBL] [Abstract][Full Text] [Related]
2. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study.
Finkel RS; Chiriboga CA; Vajsar J; Day JW; Montes J; De Vivo DC; Yamashita M; Rigo F; Hung G; Schneider E; Norris DA; Xia S; Bennett CF; Bishop KM
Lancet; 2016 Dec; 388(10063):3017-3026. PubMed ID: 27939059
[TBL] [Abstract][Full Text] [Related]
3. Long-Term Comparative Efficacy and Safety of Risdiplam and Nusinersen in Children with Type 1 Spinal Muscular Atrophy.
Kokaliaris C; Evans R; Hawkins N; Mahajan A; Scott DA; Sutherland CS; Nam J; Sajeev G
Adv Ther; 2024 Jun; 41(6):2414-2434. PubMed ID: 38705943
[TBL] [Abstract][Full Text] [Related]
4. Drug treatment for spinal muscular atrophy type I.
Wadman RI; van der Pol WL; Bosboom WM; Asselman FL; van den Berg LH; Iannaccone ST; Vrancken AF
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD006281. PubMed ID: 31825542
[TBL] [Abstract][Full Text] [Related]
5. A Post-Marketing Surveillance Study of Nusinersen for Spinal Muscular Atrophy in Routine Medical Practice in China: Interim Results.
Jiang Y; Wang Y; Xiong H; Li W; Luo R; Chen W; Yin F; Lü J; Liang J; Chen WJ; Lu X; Wang H; Tang J; Monine M; Makepeace C; Jin X; Foster R; Chin R; Berger Z
Adv Ther; 2024 Jul; 41(7):2743-2756. PubMed ID: 38722537
[TBL] [Abstract][Full Text] [Related]
6. Cerebrospinal Fluid and Clinical Profiles in Adult Type 2-3 Spinal Muscular Atrophy Patients Treated with Nusinersen: An 18-Month Single-Centre Experience.
Milella G; Introna A; D'Errico E; Fraddosio A; Scaglione G; Morea A; Ucci M; Ruggieri M; Mastrapasqua M; Megna M; Puntillo F; Simone IL
Clin Drug Investig; 2021 Sep; 41(9):775-784. PubMed ID: 34389971
[TBL] [Abstract][Full Text] [Related]
7. Effect of nusinersen on motor, respiratory and bulbar function in early-onset spinal muscular atrophy.
Pechmann A; Behrens M; Dörnbrack K; Tassoni A; Stein S; Vogt S; Zöller D; Bernert G; Hagenacker T; Schara-Schmidt U; Schwersenz I; Walter MC; Baumann M; Baumgartner M; Deschauer M; Eisenkölbl A; Flotats-Bastardas M; Hahn A; Horber V; Husain RA; Illsinger S; Johannsen J; Köhler C; Kölbel H; Müller M; von Moers A; Schlachter K; Schreiber G; Schwartz O; Smitka M; Steiner E; Stögmann E; Trollmann R; Vill K; Weiß C; Wiegand G; Ziegler A; Lochmüller H; Kirschner J;
Brain; 2023 Feb; 146(2):668-677. PubMed ID: 35857854
[TBL] [Abstract][Full Text] [Related]
8. Assessment of motor function and nutritional status in children with spinal muscular atrophy treated with nusinersen after loading period in Western China: a retrospective study.
Yang H; Tao Q; Li D; Yang J; Cai Q; Gan J; Huang S; Luo R
BMC Neurol; 2023 Jan; 23(1):35. PubMed ID: 36690929
[TBL] [Abstract][Full Text] [Related]
9. Long-term nusinersen treatment across a wide spectrum of spinal muscular atrophy severity: a real-world experience.
Łusakowska A; Wójcik A; Frączek A; Aragon-Gawińska K; Potulska-Chromik A; Baranowski P; Nowak R; Rosiak G; Milczarek K; Konecki D; Gierlak-Wójcicka Z; Burlewicz M; Kostera-Pruszczyk A
Orphanet J Rare Dis; 2023 Aug; 18(1):230. PubMed ID: 37542300
[TBL] [Abstract][Full Text] [Related]
10. Nusinersen for Spinal Muscular Atrophy Type I with Chronic Respiratory Failure: A Retrospective Study in South Korea.
Shin HJ; Na JH; Lee H; Lee YM
Yonsei Med J; 2023 Dec; 64(12):705-711. PubMed ID: 37992742
[TBL] [Abstract][Full Text] [Related]
11. Nusinersen for adults with spinal muscular atrophy.
Arslan D; Inan B; Kilinc M; Bekircan-Kurt CE; Erdem-Ozdamar S; Tan E
Neurol Sci; 2023 Jul; 44(7):2393-2400. PubMed ID: 36854931
[TBL] [Abstract][Full Text] [Related]
12. The effects of nusinersen treatment on respiratory status of children with spinal muscular atrophy.
Hepkaya E; Kılınç Sakallı AA; Ülkersoy İ; Başkan AK; Arslan H; Meral Ö; Dilek TD; Güler S; Saltık S; Çokuğraş H
Pediatr Int; 2022 Jan; 64(1):e15310. PubMed ID: 36310036
[TBL] [Abstract][Full Text] [Related]
13. Long-term efficacy of nusinersen and its evaluation in adolescent and adult patients with spinal muscular atrophy types 1 and 2.
Iwayama H; Kawahara K; Takagi M; Numoto S; Azuma Y; Kurahashi H; Yasue Y; Kawajiri H; Yanase A; Ito T; Kimura S; Kumagai T; Okumura A
Brain Dev; 2023 Feb; 45(2):110-116. PubMed ID: 36335004
[TBL] [Abstract][Full Text] [Related]
14. Safety, tolerability, and efficacy of a widely available nusinersen program for Polish children with Spinal Muscular Atrophy.
Kotulska K; Chmielewski D; Mazurkiewicz-Bełdzińska M; Tomaszek K; Pierzchlewicz K; Rabczenko D; Przysło Ł; Biedroń A; Czyżyk E; Steinborn B; Pietruszewski J; Boćkowski L; Cichosz D; Dudzińska M; Gadowska E; Młynarczyk E; Jasiński M; Masztalerz A; Kempisty A; Kostera-Pruszczyk A
Eur J Paediatr Neurol; 2022 Jul; 39():103-109. PubMed ID: 35738181
[TBL] [Abstract][Full Text] [Related]
15. Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3 - A Prospective Observational Study.
Walter MC; Wenninger S; Thiele S; Stauber J; Hiebeler M; Greckl E; Stahl K; Pechmann A; Lochmüller H; Kirschner J; Schoser B
J Neuromuscul Dis; 2019; 6(4):453-465. PubMed ID: 31594243
[TBL] [Abstract][Full Text] [Related]
16. Type I spinal muscular atrophy patients treated with nusinersen: 4-year follow-up of motor, respiratory and bulbar function.
Pane M; Coratti G; Sansone VA; Messina S; Catteruccia M; Bruno C; Sframeli M; Albamonte E; Pedemonte M; Brolatti N; Mizzoni I; D'Amico A; Bravetti C; Berti B; Palermo C; Leone D; Salmin F; De Sanctis R; Pera MC; Piastra M; Genovese O; Ricci F; Cavallina I; Masson R; Zanin R; Agosto C; Salomon E; Bruno I; Magnolato A; Bertini E; Tiziano FD; Bovis F; Mercuri E;
Eur J Neurol; 2023 Jun; 30(6):1755-1763. PubMed ID: 36880698
[TBL] [Abstract][Full Text] [Related]
17. Effects of nusinersen after one year of treatment in 123 children with SMA type 1 or 2: a French real-life observational study.
Audic F; de la Banda MGG; Bernoux D; Ramirez-Garcia P; Durigneux J; Barnerias C; Isapof A; Cuisset JM; Cances C; Richelme C; Vuillerot C; Laugel V; Ropars J; Altuzarra C; Espil-Taris C; Walther-Louvier U; Sabouraud P; Chouchane M; Vanhulle C; Trommsdorff V; Pervillé A; Testard H; Lagrue E; Sarret C; Avice AL; Beze-Beyrie P; Pauly V; Quijano-Roy S; Chabrol B; Desguerre I
Orphanet J Rare Dis; 2020 Jun; 15(1):148. PubMed ID: 32532349
[TBL] [Abstract][Full Text] [Related]
18. Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study.
Weiß C; Ziegler A; Becker LL; Johannsen J; Brennenstuhl H; Schreiber G; Flotats-Bastardas M; Stoltenburg C; Hartmann H; Illsinger S; Denecke J; Pechmann A; Müller-Felber W; Vill K; Blaschek A; Smitka M; van der Stam L; Weiss K; Winter B; Goldhahn K; Plecko B; Horber V; Bernert G; Husain RA; Rauscher C; Trollmann R; Garbade SF; Hahn A; von der Hagen M; Kaindl AM
Lancet Child Adolesc Health; 2022 Jan; 6(1):17-27. PubMed ID: 34756190
[TBL] [Abstract][Full Text] [Related]
19. Later efficacy of nusinersen treatment in adult patients with spinal muscular atrophy: A retrospective case study with a median 4-year follow-up.
Funato M; Kino A; Iwata R; Yumioka M; Yamashita K; Urui C; Uno R; Kondo E; Morioka E; Ogawa Y; Kawamura A; Kusukawa T; Minatsu H
Brain Dev; 2024 Jan; 46(1):62-67. PubMed ID: 37657961
[TBL] [Abstract][Full Text] [Related]
20. Nusinersen induces detectable changes in compound motor action potential response in spinal muscular atrophy type 1 patients with severe impairment of motor function.
Ueda Y; Egawa K; Kawamura K; Ochi N; Goto T; Kimura S; Narugami M; Nakakubo S; Nakajima M; Manabe A; Shiraishi H
Brain Dev; 2024 Mar; 46(3):149-153. PubMed ID: 38103972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]